stockrowVivos Therapeutics, Inc.
VVOS Healthcare Medical Devices
Vivos Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $17.4 million, up 16.0% from fiscal 2024.
- Revenue
- +34.9%
- EPS
- +43.6%
- Free cash flow
- +16.4%
- Total debt
- +2.79%
Quarter to June 2026, against a year earlier
Follow VVOS
Alert me
Vivos Therapeutics, Inc. (VVOS) EV/Sales
As of 6 November 2026, Vivos Therapeutics, Inc. (VVOS) trades at a EV/Sales of 0.4×. Over the past ten years it has ranged from 0.1× (August 2024) to 12.3× (April 2021); the current reading is higher than 13% of that period. That is below the Medical Devices industry median of 2.8× and below the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 1.6× | (20.19%) |
| FY2024 | 2.0× | 51.69% |
| FY2023 | 1.3× | 31.69% |
| FY2022 | 1.0× | (33.15%) |
| FY2021 | 1.5× | (67.16%) |
| FY2020 | 4.5× | (48.23%) |
| FY2019 | 8.7× | 0.00% |
| FY2018 | 8.7× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 0.7× | (41.39%) |
| Mar 2026 | 1.2× | (26.25%) |
| Dec 2025 | 1.6× | (30.72%) |
| Sep 2025 | 2.3× | 2.18% |
| 24 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| NVNO enVVeno Medical Corporation compare | −50.8× |
| AIDX 20/20 Biolabs Inc. compare | −0.7× |
| TNON Tenon Medical, Inc. compare | −0.2× |
| AMIX Autonomix Medical, Inc. compare | n/m |
| WOK WORK Medical Technology Group LTD compare | n/m |
| NUWE Nuwellis, Inc. compare | 0.0× |
| VVOS Vivos Therapeutics, Inc. | 0.4× |
| XAIR Beyond Air, Inc. compare | 1.1× |
| TRIB Trinity Biotech PLC compare | 3.0× |
| Medical Devices industry median | 2.8× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)